# A Bronchoprovocation Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CSJ117 in Adult Subjects With Mild Atopic Asthma

> **NCT03138811** · PHASE1 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 28 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** CSJ117
- **DRUG:** Placebo Comparator

## Key facts

- **NCT ID:** NCT03138811
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-12-18
- **Primary completion:** 2019-07-16
- **Final completion:** 2019-07-16
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2021-10-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03138811

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03138811, "A Bronchoprovocation Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CSJ117 in Adult Subjects With Mild Atopic Asthma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03138811. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*